Menu Search
Equities

Veracyte Inc

12V:DEU

Veracyte Inc

Actions
  • Price (EUR)37.40
  • Today's Change0.40 / 1.08%
  • Shares traded0.00
  • 1 Year change+55.83%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

  • Revenue in USD (TTM)425.33m
  • Net income in USD-9.27m
  • Incorporated2006
  • Employees815.00
  • Location
    Veracyte Inc6000 Shoreline Court, Suite 300SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 243-6300
  • Fax+1 (650) 243-6301
  • Websitehttps://www.veracyte.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		VCYT:NMQ since
announced		Transaction
value
C2i Genomics IncDeal completed08 Jan 202408 Jan 2024Deal completed54.04%95.00m
Data delayed at least 15 minutes, as of Nov 22 2024 20:56 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.